OverviewSuggest Edit

ImmuPharma is a pharmaceutical company focused on developing innovative drugs to treat serious medical conditions in specialist therapeutic areas. Its low risk-strategy is to work closely with the largest fundamental research institutions, which allows access to scientists and doctors, keeping costs low by avoiding the constant funding necessary for early-stage research. The Company offers Lupuzor, a treatment for Lupus and its most advanced drug candidate.

TypePublic
Founded1999
HQLondon, GB
Websiteimmupharma.co.uk

Latest Updates

Employees (est.) (Sept 2020)17
Revenue (FY, 2018)£81.3 K(-45%)
Share Price (Oct 2020)£0.1 (+4%)
Cybersecurity ratingAMore

Key People/Management at ImmuPharma

Tim McCarthy

Tim McCarthy

Non-Executive Chairman
Robert Zimmer

Robert Zimmer

President, Chief Science Officer & Director
Dimitri F Dimitriou

Dimitri F Dimitriou

Chief Executive Officer, Co-Founder & Director
Stéphane Méry

Stéphane Méry

Non-Executive Director
Lisa Baderoon

Lisa Baderoon

Head of Investor Relations
Sylviane Muller

Sylviane Muller

Research Director at CNRS & Co-Founder of ImmuPharma France
Show more

ImmuPharma Office Locations

ImmuPharma has offices in London, Mulhouse and Sarnen
London, GB (HQ)
50 Broadway
London, GB
1 Bartholomew Cl
Mulhouse, FR
5 Rue du Rhône
Sarnen, CH
10 Poststrasse
Show all (4)

ImmuPharma Financials and Metrics

ImmuPharma Revenue

ImmuPharma's revenue was reported to be £81.28 k in FY, 2018
GBP

Revenue (FY, 2018)

81.3k

Net income (FY, 2018)

(7.2m)

EBITDA (FY, 2018)

(7.9m)

EBIT (FY, 2018)

(8.1m)

Market capitalization (16-Oct-2020)

27.3m

Closing stock price (16-Oct-2020)

0.1

Cash (31-Dec-2018)

4.9m

EV

22.5m
ImmuPharma's current market capitalization is £27.3 m.
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

25.4k63.2k57.1k22.1m32.5k16.8k184.8k76.4k164.8k150.5k81.3k

Revenue growth, %

(59%)

Operating expense total

(1.5m)3.6m4.6m11.8m4.2m(3.8m)3.6m4.6m6.8m7.4m8.2m

EBITDA

(2.0m)(3.5m)(4.5m)10.3m(4.1m)3.9m(4.1m)(4.2m)(3.3m)(4.4m)(6.5m)(7.1m)(7.9m)
GBPFY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.01.01.0978.2k1.0m2.7m2.9m12.5m22.5m15.6m12.2m8.9m5.4m5.4m833.4k1.9m2.7m4.9m

Accounts Receivable

3.2k22.2k2.8k13.2k

Current Assets

1.01.01.0979.9k1.0m2.9m3.3m12.6m23.9m16.8m13.5m9.8m6.5m6.1m2.4m6.0m4.4m6.0m

PP&E

12.0k12.8k13.3k9.3k76.8k125.4k114.8k97.1k366.4k280.1k231.9k161.4k164.7k
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

1.4k15.1k(2.5m)(3.1m)4.7m8.1m(2.0m)(3.4m)(3.8m)(3.7m)(2.9m)(3.9m)(5.3m)(6.2m)(7.2m)

Cash From Operating Activities

15.8k18.3k879.6k3.8m(3.6m)12.0m(6.8m)(3.4m)(3.3m)(3.9m)(2.5m)(4.1m)(6.5m)(4.4m)(4.7m)

Cash From Financing Activities

977.0k3.0m(77.6k)12.0m(143.5k)555.2k165.3k356.9k191.5k3.0m(310.1k)7.4m5.4m9.1m

Net Change in Cash

978.2k27.1k2.7m3.7m8.5m11.9m(6.4m)(3.2m)(2.8m)(3.7m)199.0k(4.5m)896.3k945.9k2.3m
GBPFY, 2001

Financial Leverage

1 x
Show all financial metrics

ImmuPharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

ImmuPharma Online and Social Media Presence

Embed Graph

ImmuPharma News and Updates

Immupharma shares take off as firm signs US lupus deal

Specialist drug developer Immupharma rose almost 300 per cent today on the back of an exclusive US licensing deal for [...] The post Immupharma shares take off as firm signs US lupus deal appeared first on CityAM.

The Life Sciences Division Update Report on ImmuPharma plc Post AstraZeneca plc Announcement of Anifrolumab Successfully Navigating a Second Phase III Clinical Trial in Lupus

LONDON, Sept. 9, 2019 /PRNewswire/ -- The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announces an update report on ImmuPharma plc, a pharmaceutical development company listed on AIM of the London Stock Exchange focusing on...

The Life Sciences Division Initiates Coverage on ImmuPharma Plc With a BUY/Corporate Rating

LONDON, May 28, 2019 /PRNewswire/ -- The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announces the initiation of research on ImmuPharma plc, a pharmaceutical development company listed on AIM of the London Stock Exchange focusing on ...

ImmuPharma Blogs

Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund

ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has converted $200,000 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertibl…

Director/PDMR Shareholding/TR-1

To download click here The post Director/PDMR Shareholding/TR-1 appeared first on ImmuPharma.

Placing to raise £6.5 million – update; related party transaction

The Company announces that admission of the Placing Shares issued in the Placing (as defined in the announcement of 2 September 2020) which was expected to take place at 8.00am on or around 7 September 2020 is now expected to take place at 8.00 am on Tuesday 8 September. The Company also announces i…

Conversion of Convertible Security

ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has converted $150,000 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertibl…

Placing to raise £6.5 million

ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that in response to investor demand, it has raised £6.5 million, before expenses, via an oversubscribed Placing of 59,090,909 new ordinary shares of 10p each in the Company (“…

Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients

ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an important regulatory milestone in preparation for the new optimised international Phase III trial of  Lupuzor™ for systemic lupus erythematosus (“SLE”) a potentially life-t…
Show more

ImmuPharma Frequently Asked Questions

  • When was ImmuPharma founded?

    ImmuPharma was founded in 1999.

  • Who are ImmuPharma key executives?

    ImmuPharma's key executives are Tim McCarthy, Robert Zimmer and Dimitri F Dimitriou.

  • How many employees does ImmuPharma have?

    ImmuPharma has 17 employees.

  • What is ImmuPharma revenue?

    Latest ImmuPharma annual revenue is £81.3 k.

  • What is ImmuPharma revenue per employee?

    Latest ImmuPharma revenue per employee is £4.8 k.

  • Who are ImmuPharma competitors?

    Competitors of ImmuPharma include Bracco, Advanced Accelerator Applications and Akrivis Technologies.

  • Where is ImmuPharma headquarters?

    ImmuPharma headquarters is located at 50 Broadway, London.

  • Where are ImmuPharma offices?

    ImmuPharma has offices in London, Mulhouse and Sarnen.

  • How many offices does ImmuPharma have?

    ImmuPharma has 4 offices.